Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline FLT3 Inhibitor‐Based Therapy in FLT3‐Mutated AML

IF 9.9 1区医学 Q1 HEMATOLOGY

American Journal of Hematology Pub Date : 2025-09-02 DOI:10.1002/ajh.70053

Sankalp Arora, Sanam Loghavi, Naval Daver, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Elias Jabbour, Musa Yilmaz, Ghayas C. Issa, Justin McCormack, Omer Karrar, Sherry Pierce, Hagop Kantarjian, Nicholas J. Short

引用次数: 0

查看原文本刊更多论文

基于FLT3抑制剂的一线治疗FLT3突变AML复发和复发后结果的细胞分子机制

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Hematology 医学-血液学

CiteScore

15.70

自引率

3.90%

发文量

363

审稿时长

3-6 weeks

期刊介绍： The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.